Hal Barron, GSK R&D chief, at Endpoints News' UKBIO 2019

Glax­o­SmithK­line, Vir look to suc­ceed where Lil­ly failed with NIH an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

In the hunt for an ef­fec­tive Covid-19 ther­a­py, mon­o­clon­al an­ti­bod­ies have turned up mixed da­ta so far. Eli Lil­ly was Ex­hib­it A in Oc­to­ber when …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.